BofA analyst Craig Bijou downgraded Haemonetics (HAE) to Underperform from Neutral with a price target of $68, down from $95, after Q3 revenue ...
The image was generated by artificial intelligence. The uncropped image contains a watermark that indicates it was made with AI.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback